1. Cilomilast (Ariflo) a potent selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: Results of a 6 month trial;Edelson;American Journal of Respiratory and Critical Care Medicine,2001
2. Cilomilast (Ariflo) improves health status in patients with COPD: Results of a 6-month trial;Edelson;American Journal of Respiratory and Critical Care Medicine,2001
3. GSK CTR-039 A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg twice daily) in patients with chronic obstructive pulmonary disease http://www.gsk-clinicalstudyregister.com/files/pdf/24043.pdf.
4. Cilomilast for COPD: Results of a 6-month, placebo controlled study of a potent, selective inhibitor of phosphodiesterase 4;Rennard;Chest,2006
5. GSK CTR-042 A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg twice daily) in patients with chronic obstructive pulmonary disease http://www.gsk-clinicalstudyregister.com/files/pdf/24046.pdf.